Clinical features and treatment of adenovirus infections

Reviews in Medical Virology

Volumn 18, Issue 6, 2008, Pages 357-374

  Lenaerts, Liesbeth ^a   De Clercq, Erik ^a   Naesens, Lieve ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 7 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]PURINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; CAPSID PROTEIN; CIDOFOVIR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; NUCLEOSIDE ANALOG; RIBAVIRIN; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; DISEASE MODEL; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INNATE IMMUNITY; KERATOCONJUNCTIVITIS; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN DNA BINDING; REVIEW; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS REPLICATION;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; MICE;

EID: 57049146779     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.589     Document Type: Review

References (154)

1. Rowe W, Huebner R, Gilmore L, et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953; 84: 570-573.
2. Horwitz MS. Adenoviruses. Field Virol 2001; 2: 2149-2171.
3. Chakrabarti S, Milligan DW, Moss PA, et al. Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management. Leuk Lymphoma 2004; 45: 873-885.
4. Nemerow GR. Cell receptors involved in adenovirus entry. Virology 2000; 274: 1-4.
5. Vellinga J, Van der Heijdt S, Hoeben RC. The adenovirus capsid: major progress in minor proteins. J Gen Virol 2005; 86: 1581-1588.
6. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003; 13: 155-171.
7. Cohen CJ, Shieh JT, Pickles RJ, et al. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001; 98: 15191-15196.
8. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412.
9. Short JJ, Pereboev AV, Kawakami Y, et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004; 322: 349-359.
10. Arnberg N, Kidd AH, Edlund K, et al. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v) integrins. J Virol 2000; 74: 7691-7693.
11. Dechecchi MC, Melotti P, Bonizzato A, et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
12. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
13. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81: 2573-2604.
14. Mul YM, Verrijzer CP, van der Vliet PC. Transcription factors NFI and NFIII/oct-1 function independently, employing different mechanisms to enhance adenovirus DNA replication. J Virol 1990; 64: 5510-5518.
15. Brenkman AB, Breure EC, van der Vliet PC. Molecular architecture of adenovirus DNA polymerase and location of the protein primer. J Virol 2002; 76: 8200-8207.
16. Leegwater PA, Rombouts RF, van der Vliet PC. Adenovirus DNA replication in vitro: duplication of single-stranded DNA containing a panhandle structure. Biochim Biophys Acta 1988; 951: 403-410.
17. Tollefson AE, Scaria A, Hermiston TW, et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for ef.cient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296-2306.
18. Brandt CD, Kim HW, Vargosko AJ, et al. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol 1969; 90: 484-500.
19. Sivan AV, Lee T, Binn LN, et al. Adenovirus-associated acute respiratory disease in healthy adolescents and adults: a literature review. Mil Med 2007; 172: 1198-1203.
20. Warren D, Nelson KE, Farrar JA, et al. A large outbreak of epidemic keratoconjunctivitis: problems in controlling nosocomial spread. J Infect Dis 1989; 160: 938-943.
21. Hierholzer JC. Adenoviruses in the immunocompromised host. Clin Microbiol Rev 1992; 5: 262-274.
22. Howard DS, Phillips II GL, Reece DE, et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999; 29: 1494-1501.
23. Schilham MW, Claas EC, van Zaane W, et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis 2002; 35: 526-532.
24. Echavarria M, Forman M, van Tol MJ, et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358: 384-385.
25. Garnett CT, Erdman D, Xu W, et al. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002; 76: 10608-10616. 26. Fender P, Kidd AH, Brebant R, et al. Antigenic sites on the receptor-binding domain of human adenovirus type 2 fibre. Virology 1995; 214: 110-117.
26. Varghese R, Mikyas Y, Stewart PL, et al. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J Virol 2004; 78: 12320-12332.
27. Hong SS, Habib NA, Franqueville L, et al. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J Virol 2003; 77: 10366-10375.
28. Kitchen LW, Vaughn DW. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. Vaccine 2007; 25: 7017-7030.
29. Heemskerk B, Veltrop-Duits LA, van Vreeswijk T, et al. Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol 2003; 77: 6562-6566.
30. Leen AM, Sili U, Vanin EF, et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 2004; 104: 2432-2440.
31. Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191: 520-530.
32. Olive M, Eisenlohr LC, Flomenberg P. Quantitative analysis of adenovirus-speci.c CD4_T-cell responses from healthy adults. Viral Immunol 2001; 14: 403-413.
33. Tang J, Olive M, Pulmanausahakul R, et al. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 2006; 350: 312-322.
34. Heemskerk B, van Vreeswijk T, Veltrop-Duits LA, et al. Adenovirus-specific CD4+ T cell clones recognizing endogenous antigen inhibit viral replication in vitro through cognate interaction. J Immunol 2006; 177: 8851-8859.
35. Nazir SA, Metcalf JP. Innate immune response to adenovirus. J Investig Med 2005; 53: 292-304.
36. Mistchenko AS, Diez RA, Mariani AL, et al. Cytokines in adenoviral disease in children: association of interleukin-6, interleukin-8, and tumor necrosis factor alpha levels with clinical outcome. J Pediatr 1994; 124: 714-720.
37. Brunetti-Pierri N, Palmer DJ, Beaudet AL, et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
38. Muruve DA, Cotter MJ, Zaiss AK, et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 2004; 78: 5966-5972.
39. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007; 81: 3170-3180.
40. De Clercq E, Hol A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4: 928-940.
41. Mul YM, van Miltenburg RT, De Clercq E, et al. Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp: influence of the adenovirus DNA binding protein. Nucleic Acids Res 1989; 17: 8917-8929.
42. Gordon YJ, Araullo-Cruz TP, Johnson YF, et al. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir. Invest Ophthalmol Vis Sci 1996; 37: 2774-2778.
43. Kinchington PR, Araullo-Cruz T, Vergnes JP, et al. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir. Antiviral Res 2002; 56: 73-84.
44. Bischofberger N, Hitchcock MJ, Chen MS, et al. 1-[((S) -2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994; 38: 2387-2391.
45. Hartline CB, Gustin KM, Wan WB, et al. Ether lipidester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191: 396-399.
46. Quenelle DC, Collins DJ, Wan WB, et al. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004; 48: 404-412.
47. Krecmerova M, Hol A, Piskala A, et al. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2- (phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J Med Chem 2007; 50: 1069-1077.
48. Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005; 49: 1010-1016.
49. Wildner O, Hoffmann D, Jogler C, et al. Comparison of HSV-1 thymidine kinase-dependent and - independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther 2003; 10: 791-802.
50. Neyts J, Balzarini J, Andrei G, et al. Intracellular metabolism of the N7-substituted acyclic nucleoside analog 2-amino-7-(1,3-dihydroxy-2-propoxymethyl) purine, a potent inhibitor of herpesvirus replication. Mol Pharmacol 1998; 53: 157-165.
51. Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006; 16: 37-48.
52. Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther 2005; 10: 225-229.
53. Georgopapadakou N. Discontinued drugs in 2005: anti-infectives. Expert Opin Investig Drugs 2007; 16: 1-10.
54. Mentel R, Kurek S, Wegner U, et al. Inhibition of adenovirus DNA polymerase by modified nucleoside triphosphate analogs correlate with their anti-viral effects on cellular level. Med Microbiol Immunol (Berl) 2000; 189: 91-95.
55. van der Vliet PC, Kwant MM. Role of DNA polymerase gamma in adenovirus DNA replication. Mechanism of inhibition by 2′,3′-dideoxynucleoside 5′-triphosphates. Biochemistry 1981; 20: 2628-2632.
56. Daluge SM, Purifoy DJ, Savina PM, et al. 5-Chloro-2′,3′-dideoxy-3′-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother 1994; 38: 1590-1603.
57. Uckun FM, Pendergrass S, Qazi S, et al. Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro anti-viral activity against adenovirus. Eur J Med Chem 2004; 39: 225-234.
58. Bruno B, Gooley T, Hackman RC, et al. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003; 9: 341-352.
59. Gavin PJ, Katz BZ. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 2002; 110: e9.
60. Arav-Boger R, Echavarria M, Forman M, et al. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr Infect Dis J 2000; 19: 1097-1100.
61. Abe S, Miyamura K, Oba T, et al. Oral ribavirin for severe adenovirus infection after allogeneic marrow transplantation. Bone Marrow Transplant 2003; 32: 1107-1108.
62. Cassano WF. Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1991; 7: 247-248.
63. Emovon CIE, Lin A, Howell DN, et al. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol Dial Transplant 2003; 18: 2436-2438.
64. Fanourgiakis P, Georgala A, Vekemans M, et al. Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis 2005; 40: 199-201.
65. Homma M, Inoue Y, Hasegawa Y, et al. Blood ribavirin concentration in high-dose ribavirin for adenovirus-induced haemorrhagic cystitis - a case report. J Clin Pharm Ther 2008; 33: 75-78.
66. Jurado M, Navarro JM, Hernandez J, et al. Adenovirus-associated haemorrhagic cystitis after bone marrow transplantation successfully treated with intravenous ribavirin. Bone Marrow Transplant 1995; 15: 651-652.
67. Kapelushnik J, Or R, Delukina. M, et al. Intravenous ribavirin therapy for adenovirus gastroenteritis after bone marrow transplantation. J Pediatr Gastroenterol Nutr 1995; 21: 110-112.
68. Liles WC, Cushing H, Holt S, et al. Severe adenoviral nephritis following bone marrow transplantation: successful treatment with intravenous ribavirin. Bone Marrow Transplant 1993; 12: 409-412.
69. McCarthy AJ, Bergin M, De Silva LM, et al. Intravenous ribavirin therapy for disseminated adenovirus infection. Pediatr Infect Dis J 1995; 14: 1003-1004.
70. Murphy GF, Wood DP Jr., McRoberts JW, et al. Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin. J Urol 1993; 149: 565-566.
71. Sabroe I, McHale J, Tait DR, et al. Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin. Thorax 1995; 50: 1219-1220.
72. Shetty AK, Gans HA, So S, et al. Intravenous ribavirin-therapy for adenovirus pneumonia. Pediatr Pulmonol 2000; 29: 69-73.
73. Wulffraat NM, Geelen SP, van Dijken PJ, et al. Recovery from adenovirus pneumonia in a severe combined immunodeficiency patient treated with intravenous ribavirin. Transplantation 1995; 59: 927.
74. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 2004; 23: 583-588.
75. Crooks BN, Taylor CE, Turner AJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant 2000; 26: 1097-1102.
76. Hromas R, Clark C, Blanke C, et al. Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation. Bone Marrc Transplant 1994; 14: 663-664.
77. Lankeste, Heemskerk B, Claas EC, et al. Effect of ribavirine on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38: 1521-1525.
78. Hillenkamp J, Reinhard T, Ross RS, et al. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral kerato-conjunctivitis: a controlled clinical pilot study. Ophthalmology 2002; 109: 845-850.
79. Hillenkamp J, Reinhard T, Ross RS, et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol 2001; 119: 1487-1491.
80. Gordon YJ, Naesens L, DeClercq E, et al. Treatment of adenoviral conjunctivitis with topical cidofovir. Cornea 1996; 15: 546.
81. Castleton A, Kottaridis PD. A case of 'red eye' post allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 241-242.
82. Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al. High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant 2008; 12: 219-227.
83. Doan ML, Mallory GB, Kaplan SL, et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant 2007; 26: 883-889.
84. Leruez-Ville M, Minard V, Lacaille F, et al. Real-time \ blood plasma polyrnerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004; 38: 45-52.
85. Muller WJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41: 1812-1816.
86. Nagafuji K, Aoki K, Henzan H, et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34: 909-914.
87. Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13: 74-81.
88. Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81: 1398-1404.
89. Gorczynska E, Turkiewicz D, Rybka K, et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 797-804.
90. Symeonidis N, Jakubowski A, Pierre-Louis S,, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Trans Infect Dis 2007; 9: 108-113.
91. Kalpoe JS, van der Heiden PL, Barge RM, et al. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning. Eur J Haematol 2007, 78: 314-321.
92. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 2005; 130: 595-603.
93. Sivaprakasam P, Carr TF, Coussons; M, et al. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. J Pediatr Hematol Oncol 2007; 29: 81-85.
94. Lankester AC, van Tol MJ, Claas EC, et al. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin Infect Dis 2002; 34: 864-867.
95. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619-1627.
96. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004; 10: 186-194.
97. van Tol MJ, Kroes AC, Schinkel J, et al. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant 2005; 36: 39-50.
98. Kaneko H, Kato K, Mori S, et al. Antiviral activity of NMS03 against adenovirus in vitro. Antiviral Res 2001; 52: 281-288.
99. Johansson SM, Nilsson EC, Elofsson M, et al. Multivalent sialic acid conjugates inhibit adenovirus type 37 from binding to and infecting human corneal epithelial cells. Antiviral Res 2007; 73: 92-100.
100. Mangel WF, Baniecki ML, McGrath WJ. Specific interactions of the adenovirus proteinase with the viral DNA, an 11-amino-add viral peptide, and the cellular protein actin. Cell Mol Life Sci 2003; 60: 2347-2355.
101. Sircar S, Ruzindana-Umunyana A, Neugebauer W, et al. Adenovirus endopeptidase and papain are inhibited by the same agents. Antiviral Res 1998; 40: 45-51.
102. Weber JM, Ruzindana-Umunyana A, Imbeault L, et al. Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res 2003; 58: 167-173.
103. McGrath WJ, Abola AP, Toledo DL, et al. Characterization of human adenovirus proteinase activity in disrupted virus particles. Virology 1996; 217: 131-138.
104. Cao W, Baniecki ML, McGrath WJ, et al. Nitric oxide inhibits the adenovirus proteinase in vitro and viral infectivity in vivo. FASEB J 2003; 17: 2345-2346.
105. Pang YP, Xu K, Kollmeyer TM, et al. Discovery of a new inhibitor lead of adenovirus proteinase: steps toward selective, irreversible inhibitors of cysteine proteinases. FEBS Lett 2001; 502: 93-97.
106. Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res 2005; 30: 505-515.
107. Nagl M, Larcher C, Gottardi W. Activity of N-chlorotaurine against herpes simplex- and adenoviruses. Antiviral Res 1998; 38: 25-30.
108. Teuchner B, Nagl M, Schidlbauer A, et al. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis-a double-blind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther 2005; 21: 157-165.
109. Horne WS, Wiethoff CM, Cui C, et al. Antiviral cyclic D,L-alpha-peptides: targeting a general biochemical pathway in virus infections. Bioorg Med Chem 2005; 13: 5145-5153.
110. Zarubaev VV, Slita AV, Krivitskaya VZ, et al. Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro. Antiviral Res 2003; 58: 131-137.
111. Arnold D, Di Biase AM, Marchetti M, et al. Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res 2002; 53: 153-158.
112. Chiang LC, Cheng HY, Liu MC, et al. In vitro anti-herpes simplex viruses and anti-adenoviruses activity of twelve traditionally used medicinal plants in Taiwan. Biol Pharm Bull 2003; 26: 1600-1604.
113. Epstein SP, Pashinsky YY, Gershon D, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmol 2006; 6: 22.
114. Das A, Trousdale MD, Ren S, et al. Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate. Antiviral Res 1999; 44: 201-208.
115. Hippenmeyer PJ, Ruminski PG, Rico JG, et al. Adenovirus inhibition by peptidomimetic integrin antagonists. Antiviral Res 2002; 55: 169-178.
116. Chung YS, Kim MK, Lee WJ, et al. Silencing E1A mRNA by RNA interference inhibits adenovirus replication. Arch Virol 2007; 152: 1305-1314.
117. Chakrabarti S, Collingham KE, Fegan CD, et al. Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow Transplant 2000; 26: 305-307.
118. Hromas R, Cornetta K, Srour E, et al. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994; 84: 1689-1690.
119. Lucas KG, Sun Q, Burton RL, et al. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther 2000; 11: 1453-1463.
120. Bordigoni P, Carret AS, Venard V, et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32: 1290-1297.
121. Chatziandreou I, Gilmour KC, McNicol AM, et al. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br J Haematol 2007; 136: 117-126.
122. Feuchtinger T, Lang P, Hamprecht K, et al. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 2004; 32: 282-289.
123. Leen AM, Myers GD, Bollard CM, et al. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci 2005; 1062: 104-115.
124. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64-76.
125. Heemskerk B, Veltrop-Duits LA, van Vreeswijk T, et al. Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol 2003; 77: 6562-6566.
126. Dagan R, Schwartz RH, Insel RA, et al. Severe diffuse adenovirus 7a pneumonia in a child with combined immunodeficiency: possible therapeutic effect of human immune serum globulin containing specific neutralizing antibody. Pediatr Infect Dis 1984; 3: 246-251.
127. Pacini DL, Dubovi EJ, Clyde WA Jr. A new animal model for human respiratory tract disease due to adenovirus. J Infect Dis 1984; 150: 92-97.
128. Ginsberg HS, Moldawer LL, Sehgal PB, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1991; 88: 1651-1655.
129. Kajon AE, Gigliotti AP, Harrod KS. Acute inflammatory response and remodeling of airway epithelium after subspecies B1 human adenovirus infection of the mouse lower respiratory tract. J Med Virol 2003; 71: 233-244.
130. Mentel R, Wegner U. Evaluation of the efficacy of 2′,3′-dideoxycytidine against adenovirus infection in a mouse pneumonia model. Antiviral Res 2000; 47: 79-87.
131. Gordon YJ, Romanowski E, Araullo-Cruz T. An ocular model of adenovirus type 5 infection in the NZ rabbit. Invest Ophthalmol Vis Sci 1992; 33: 574-580.
132. Kaneko H, Mori S, Suzuki O, et al. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Antiviral Res 2004; 61: 63-66.
133. Tsai JC, Garlinghouse G, McDonnell PJ, et al. An experimental animal model of adenovirus-induced ocular disease. The cotton rat. Arch Ophthalmol 1992; 110: 1167-1170.
134. de Oliveira CB, Stevenson D, LaBree L, et al. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res 1996; 31: 165-172.
135. Gordon YJ, Romanowski EG, Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci 1994; 35: 4135-4143.
136. Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/ New Zealand rabbit ocular model. Antiviral Res 2001; 52: 275-280.
137. Nwanegbo EC, Romanowski EG, Gordon YJ, et al. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection. Invest Ophthalmol Vis Sci 2007; 48: 4171-4176.
138. Romanowski EG, Yates KA, Teuchner B, et al. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Invest Ophthalmol Vis Sci 2006; 47: 2021-2026.
139. Epstein SP, Pashinsky YY, Gershon D, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmol 2006; 6: 22.
140. Moore ML, McKissic EL, Brown CC, et al. Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase. J Virol 2004; 78: 5584-5590.
141. Pirofski L, Horwitz MS, Scharff MD, et al. Murine adenovirus infection of SCID mice induces hepatic lesions that resemble human Reye syndrome. Proc Natl Acad Sci USA 1991; 88: 4358-4362.
142. Charles PC, Guida JD, Brosnan CF, et al. Mouse adenovirus type-1 replication is restricted to vascular endothelium in the CNS of susceptible strains of mice. Virology 1998; 245: 216-228.
143. Guida JD, Fejer G, Pirofski LA, et al. Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice. J Virol 1995; 69: 7674-7681.
144. Lenaerts L, Verbeken E, De Clercq E, et al. Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections. Antimicrob Agents Chemother 2005; 49: 4689-4699.
145. Lenaerts L, Kelchtermans H, Geboes L, et al. Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection. Antimicrob Agents Chemother 2008; 52: 1462-1471.
146. Tuve S, Wang H, Ware C, et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 2006; 80: 12109-12120.
147. Gordon YJ, Romanowski E, Araullo-Cruz T, et al. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 20-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res 1991; 16: 11-16.
148. Kodama E, Shigeta S, Suzuki T, et al. Application of a gastric cancer cell line (MKN-28) for antiadenovirus screening using the MTT method. Antiviral Res 1996; 31: 159-164.
149. Stock R, Harste G, Madisch I, et al. A rapid quantitative PCR-based assay for testing antiviral agents against human adenoviruses demonstrates type specific differences in ribavirin activity. Antiviral Res 2006; 72: 34-41.
150. Baba M, Mori S, Shigeta S, et al. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2′-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother 1987; 31: 337-339.
151. Trousdale MD, Goldschmidt PL, Nobrega R. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea 1994; 13: 435-439.
152. Mentel R, Kinder M, Wegner U, et al. Inhibitory activity of 3′-fluoro-2′ deoxythymidine and related nucleoside analogues against adenoviruses in vitro. Antiviral Res 1997; 34: 113-119.
153. Kirsi JJ, North JA, McKernan PA, et al. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother 1983; 24: 353-361.
154. Zarubalev VV, Slita AV, Sukhinin VP, et al. Effect of 6-azacytidine on the course of experimental adenoviral infection in newborn Syrian hamsters. J Chemother 2007; 19: 44-51.